PolyViewer is an independent, read-only information viewer. It does not provide trading, financial, investment, gambling, or legal advice. Forecast data comes from Polymarket. Users are responsible for verifying applicable laws and restrictions in their jurisdiction and assume all responsibility for how they use this information.

PolyViewer is not affiliated with or endorsed by Polymarket.

PolyViewer

Forecast data supplied by Polymarket's public APIs.

2026 PolyViewer. Read-only market viewer.

Developed by Felipe Moreno

Will the FDA give emergency use authorization or otherwise approve Paxlovid before 2022? | PolyViewer

Back to forecasts

ResolvedAll

Will the FDA give emergency use authorization or otherwise approve Paxlovid before 2022?

Closed: January 1, 2022

Volume$146.8K

24h volume$0

Liquidity$0

Main forecast actors

Compare how the leading outcomes have moved over time.

Current outcomes

ResolvedVolume: $146.8K

Will the FDA give emergency use authorization or otherwise approve Paxlovid before 2022?

Yes100%

No0%

About this event

This market will resolve to “Yes” if, by December 31, 2021, 11:59:59 PM ET, Paxlovid (also known under PF-07321332), or any product containing PF-07321332 receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19. Otherwise, this market will resolve to “No.” If the resolution source isn’t updated by the resolution date, credible news reports may be used instead. Learn more about Paxlovid: https://apnews.com/article/coronavirus-pandemic-science-business-health-medication-eeea3c6a5f6428479e35bc1bcd7aec52.

Resolution source

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs

MAX

Price history is unavailable for this market and range.